Next Article in Journal
Glucose Serum Concentrations and Cardiovascular Disease in Patients on the End Stage of Renal Disease without Diabetes Mellitus
Next Article in Special Issue
Rationale for the Cytogenomics of Cardiovascular Malformations Consortium: A Phenotype Intensive Registry Based Approach
Previous Article in Journal / Special Issue
N-acetylglucosamine-1-Phosphate Transferase Suppresses Lysosomal Hydrolases in Dysfunctional Osteoclasts: A Potential Mechanism for Vascular Calcification
Article Menu

Export Article

Open AccessArticle
J. Cardiovasc. Dev. Dis. 2015, 2(2), 48-65;

Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities

Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris 75005 France
Division of Cardiology, Johns Hopkins University, Baltimore, MD 21287, USA
Paris Cardiovascular Research Center, INSERM U970, Paris 75016 France
Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris 75016 France
Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29403, USA
Cardiac Ultrasound Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114 USA
Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853 USA
INSERM U582, University Pierre et Marie Curie-Paris 6, IFR14, Paris 75005 France
Institut de recherche des Cordeliers, INSERM U652, Paris 75005, France
Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany
Author to whom correspondence should be addressed.
Academic Editor: Cheryl L. Maslen
Received: 13 February 2015 / Revised: 3 April 2015 / Accepted: 7 April 2015 / Published: 21 April 2015
(This article belongs to the Special Issue Genetics and Cardiovascular Development and Disease)
Full-Text   |   PDF [5464 KB, uploaded 21 April 2015]   |  


MYBPC3 mutations cause hypertrophic cardiomyopathy, which is frequently associated with mitral valve (MV) pathology. We reasoned that increased MV size is caused by localized growth factors with paracrine effects. We used high-resolution echocardiography to compare Mybpc3-null, heterozygous, and wild-type mice (n = 84, aged 3–6 months) and micro-CT for MV volume (n = 6, age 6 months). Mybpc3-null mice showed left ventricular hypertrophy, dilation, and systolic dysfunction compared to heterozygous and wild-type mice, but no systolic anterior motion of the MV or left ventricular outflow obstruction. Compared to wild-type mice, echocardiographic anterior leaflet length (adjusted for left ventricular size) was greatest in Mybpc3-null mice (1.92 ± 0.08 vs. 1.72 ± 0.08 mm, p < 0.001), as was combined leaflet thickness (0.23 ± 0.04 vs. 0.15 ± 0.02 mm, p < 0.001). Micro-CT analyses of Mybpc3-null mice demonstrated increased MV volume (0.47 ± 0.06 vs. 0.15 ± 0.06 mm3, p = 0.018) and thickness (0.35 ± 0.04 vs. 0.12 ± 0.04 mm, p = 0.002), coincident with increased markers of TGFβ activity compared to heterozygous and wild-type littermates. Similarly, excised MV from a patient with MYBPC3 mutation showed increased TGFβ activity. We conclude that MYBPC3 deficiency causes hypertrophic cardiomyopathy with increased MV leaflet length and thickness despite the absence of left ventricular outflow-tract obstruction, in parallel with increased TGFβ activity. MV changes in hypertrophic cardiomyopathy may be due to paracrine effects, which represent targets for therapeutic studies. View Full-Text
Keywords: mitral valve; TGFβ; hypertrophic cardiomyopathy mitral valve; TGFβ; hypertrophic cardiomyopathy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Judge, D.P.; Neamatalla, H.; Norris, R.A.; Levine, R.A.; Butcher, J.T.; Vignier, N.; Kang, K.H.; Nguyen, Q.; Bruneval, P.; Perier, M.-C.; Messas, E.; Jeunemaitre, X.; de Vlaming, A.; Markwald, R.; Carrier, L.; Hagège, A.A. Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities. J. Cardiovasc. Dev. Dis. 2015, 2, 48-65.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Cardiovasc. Dev. Dis. EISSN 2308-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top